SEC For	m 4 FORM	4	UNITED S	TATE	S SI	ECUR	ITIE	ES AND	EXCHA	NGE C	OMMI	SSION					
Washington, D.C										on, D.C. 20549					OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						NT OF CHANGES IN BENEFICIAL OWNE I pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							Estimated average burden			3235-0287 n 0.5	
1. Name and Address of Reporting Person* FORMELA JEAN FRANCOIS						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Ikena Oncology, Inc.</u> [ IKNA ]							cable) or	10% 0		vner	
(Last) (First) (Middle) C/O IKENA ONCOLOGY, INC.					3. Date of Earliest Transaction (Month/Day/Year) 12/21/2021							Officer below)	(give title Other (spe below)			specify	
645 SUMMER STREET, SUITE 101					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ne)					
(Street) BOSTON MA 02210												X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)																	
		Tab	le I - Non-D	erivati	ve Se	curities	s Ac	quired, D	isposed c	of, or Be	neficial	ly Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				te	Year)	2A. Deem Execution if any (Month/Da	Date	e, Transaction Dispo Code (Instr. 5)		ities Acquire d Of (D) (Ins		Beneficia Owned F	es For ally (D) Following (I) (I		Ownership rm: Direct or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3 a	action(s)			(Instr. 4)	
		1	Fable II - Dei (e.ç					uired, Dis s, options				Owned		-			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	4. Trans	saction (Instr.	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$14.92	12/21/2021		A		13,419		(1)	12/21/2031	Common Stock	13,419	\$0.00	13,419	9	D <sup>(2)</sup>		

## Explanation of Responses:

1. This option shall vest (1) 25% on December 21, 2022, and the remaining shall vest in equal monthly installments over the next 36 months.

2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

## Remarks:

/s/ Ommer Chohan, as Francois Formela

Attorney-in-Fact for Jean

12/23/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.